Investing Center Preview – Manage your investments and watch your net worth grow.
DSNKY:OTC Pink - Limited Information – Large Cap Stock ()
Daiichi Sankyo Co Ltd – DSNKY Stock Overview
Last Price | Today's Change | 52-Week Range | Trading Volume |
---|---|---|---|
21.88 | -0.29 (-1.31%) | 20.92 - 42.48 | 477.8 thousand (Above Avg) |
Market data as of 3:59PM 04/11/25. Quotes are delayed by at least 15 min.
Overview - DSNKY
Open | 20.92 |
---|---|
Previous Close | 22.17 |
Day's Range | 20.92 - 21.95 |
Market Cap | 41.8B |
Avg Volume (10 Day) | 409.7K |
Price/Earnings (Trailing 12 Mo.) | 26.6x |
Earnings Per Share (Trailing 12 Mo.) | 23.555 |
Dividend Yield | 0.1966 (1.77%) |
One-Click Scorecard - DSNKY


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Performed well consistently? | Neutral |
---|---|
Avoids excess debt? | Neutral |
Converting sales to profits? | Neutral |
Shareholder's money handled rationally? | Neutral |
Increased shareholder value? | Neutral |
Consistently increased owner earnings? | Neutral |
Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Pays a cash dividend? | Neutral |
---|---|
Room to increase dividends? | Neutral |
Increased earnings over time? | Neutral |
Borrows within reasonable limits? | Neutral |
Stock is undervalued? | Neutral |
Have investors caught on? | Neutral |
Has support of institutional investors? | Neutral |
Has sufficient liquidity? | Neutral |
Latest Headlines - DSNKY
DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Business Wire - Tuesday 04/08/2025 2:30 AM ET
ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy
Business Wire - Friday 04/04/2025 2:00 AM ET
DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer
Business Wire - Monday 03/31/2025 8:00 AM ET
Industry Position - DSNKY
DSNKY | Industry Range | |
---|---|---|
Revenue Growth (1yr) | 25.28% | |
Net Income Growth (1yr) | 83.84% | |
Total Debt/Equity | 0.06 | |
LT Debt/Equity | 0.06 | |
Earnings Yield | 3.76% | |
Price/Sales | 3.64 |
Competitors - DSNKY
Company | Last | Change |
---|
Data is delayed by at least 15 min.